Navigation Links
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
Date:4/25/2009

n-based therapy.

Overall, adverse events observed were those typically associated with interferon therapy, and most were similar for 900-mcg albinterferon alfa-2b and peginterferon alfa-2a.

About the Design of the ACHIEVE Trials

The albinterferon alfa-2b Phase 3 clinical development program included two randomized, multi-center, active-controlled non-inferiority Phase 3 trials -- ACHIEVE 1 and ACHIEVE 2/3. In ACHIEVE 1, 1331 treatment-naive patients with genotype 1 chronic hepatitis C were initially assigned to one of three treatment groups, including two groups that received subcutaneously administered albinterferon alfa-2b once every two weeks at doses of 900 mcg or 1200 mcg, and an active control group that received peginterferon alfa-2a once weekly at a dose of 180 mcg - with all patients receiving daily oral ribavirin concomitantly. In ACHIEVE 2/3, 933 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C were initially assigned to one of three treatment groups receiving the same doses on the same schedule of administration used in the ACHIEVE 1 study.

In January 2008, a dose modification was made in both studies for patients originally assigned to receive the 1200-mcg dose of albinterferon alfa-2b. These patients had their dose reduced to 900-mcg albinterferon alfa-2b every two weeks. Following the dose modification, both ACHIEVE 1 and ACHIEVE 2/3 continued to follow all patients randomized on an intention-to-treat (ITT) basis according to their original dose assignment. The primary data analysis in both studies compared the 900-mcg albinterferon alfa-2b treatment group to the peginterferon alfa-2a treatment group. The ACHIEVE 1 trial included 48 weeks of treatment, and the ACHIEVE 2/3 trial included 24 weeks of treatment. The primary efficacy endpoint for both trials was sustained virologic response (SVR), defined as undetectable viral load (HCV RNA<10 IU/mL
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
2. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. First Human Study to Show Sun Chlorella A Supports Heart Health
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
7. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
8. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
9. Drug Development Program Started Based on CAP(R) Human Cell Line
10. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
11. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Dec 12, 2014 Mindray Medical International Limited ... manufacturer and marketer of medical devices worldwide, today announced ... shareholders held in Hong Kong ... Mindray shareholders voted to re-elect incumbent directors Li Xiting ... Mindray,s shareholders did not re-elect Peter Wan ...
(Date:12/13/2014)... INDIANAPOLIS , Dec. 12, 2014  Novo ... Racing Teams (CGRT), today announced a multi-year extension of their ... of the No. 83 Novo Nordisk Chip Ganassi Racing entry, ... Series. Kimball, 29, from Camarillo, ... with diabetes in the history of INDYCAR to win a ...
(Date:12/13/2014)... DUBLIN , Dec. 11, 2014 Research ... announced the addition of the "China Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... of chemical drug preparation and active pharmaceutical ingredient ... preparation industry is generally higher than that of ...
Breaking Medicine Technology:Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7China Chemical Pharmaceutical Industry Report, 2013-2016 2China Chemical Pharmaceutical Industry Report, 2013-2016 3
... PRINCETON, N.J. , June 14 Covance Inc. (NYSE: ... Company,s 30th Annual Growth Stock Conference on Wednesday, June 16, 2010 ... the presentation at www.covance.com .  In order to register and download any ... , , ...
... June 14 MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ... Cheshire, England to manage its planned Phase IIb clinical trial ... candidate for treatment of primary multiple sclerosis-related fatigue (PMSF). , ... In an earlier Phase IIa study, MCT-125 ...
Cached Medicine Technology:MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 2MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 3MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... to lose weight might consider heading to the cardio ... out this month. // ,Both those who ... of weight, according to findings from an NIH-funded study ... while exercisers maintained their strength and muscle mass and ...
... produced a vaccine that activates the immune systems in ... ,During a clinical trial of 67 patients, researchers ... vaccines were injected pre and post surgery of the ... nearly 70 percent of patients. The November 15 issue ...
... drinks works as well as some sports drinks like Gatorade. ... and conducted by Indiana University // suggested found that ... 50% longer than those drinking a carbohydrate drink, an effect ... ,The story was picked up as mainstream news in ...
... memory during and after menopause, a change thought to be ... during that time. // ,Now, research from the ... help women retain certain memory functions. In a study in ... Metabolism, they report that a group of postmenopausal women showed ...
... hearing damage from acoustic shock, say health experts. // , ... functioning of the ear or of the nervous system, which ... earphone by a sudden sharp rise in the acoustic pressure ... a bleep or any unexpected noise. Two thirds of call ...
... identified by scientists from the Wistar Institute in Philadelphia and ... repression of the p53 protein // which is the most ... ,The new molecular pathway described in the study suggests ... many types of cancer. A report on the team's findings ...
Cached Medicine News:Health News:New Study Weighs Benefits of Exercise, Diets 2Health News:A novel vaccine proves a shot in the arm for colorectal cancer patients 2Health News:Hormone Therapy May Improve the Trip Down Memory Lane 2Health News:Regulatory Mechanism for Tumor Suppressor Protein Identified 2Health News:Regulatory Mechanism for Tumor Suppressor Protein Identified 3
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... Chrome plated brass. The Laryngoscope handle that ... secret is the o-rings which create a ... you to keep the batteries in when ... a high quality standard/conventional chrome-plated brass handle ...
... with blade. Rusch offers a reliable tradition ... The designs of these blades have been ... the world over to minimize maintenance requirements. ... the finest surgical grade stainless steel to ...
... laryngoscope blades are designed with the clinician ... bundle can be removed to simplify cleaning ... areas. Our unique snap-on mechanism eliminates screws ... blades are interchangeable with other green coded ...
Medicine Products: